Slowing, Not Stopping, Alzheimer's a Better Goal for Drug Trials?

A report from an Alzheimer's Association work group says it's time to reframe the meaning of 'clinically meaningful' and change expectations of outcomes from clinical drug trials.

Related Keywords

Minnesota ,United States ,University Of Pennsylvania ,Pennsylvania ,Washington University ,Missouri ,Philadelphia ,Christopher Weber ,Jason Karlawish ,Joels Perlmutter ,Alzheimers Dement ,Ronaldc Petersen ,Genentech ,Drug Administration ,Washington University School Of Medicine ,Journal Of The Alzheimer Association ,Alzheimer Association ,Penn Memory Center ,Nestle ,Mayo Clinic ,Medscape Medical ,Clinical Dementia Rating ,Medscape Medical News ,Memory Center ,Washington University School ,Alzheimers Disease ,Lzheimer Disease ,Drug Development ,Experimental Drug ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Medicare Drug Benefit ,Clinical Research ,Clinical Trials ,Linical Studies ,Cognition ,Dementia ,Memory ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Ethics ,Patient Safety ,Adverse Effects ,Tide ,